• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clinical features, sex differences and outcomes of myocardial infarction with nonobstructive coronary arteries: a registry analysis
Conclusion The incidence of MINOCA was 9.5%. Compared to OACD-MI, patients with MINOCA have less cardiac risk factors. In-hospital outcomes of patients diagnosed with MINOCA were better than OACD-MI.
Source: Coronary Artery Disease - December 23, 2020 Category: Cardiology Tags: Acute Coronary Syndromes Source Type: research

Association Between Sex and Treatment Outcomes of Atrial Fibrillation Ablation Versus Drug Therapy: Results from the CABANA Trial.
Conclusions: Clinically relevant treatment-related strategy differences in the primary and secondary clinical outcomes of CABANA were not seen between men and women, and there were no sex differences in adverse events. The CABANA trial results support catheter ablation as an effective treatment strategy for both women and men. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT00911508. PMID: 33499668 [PubMed - as supplied by publisher]
Source: Circulation - January 27, 2021 Category: Cardiology Authors: Russo AM, Zeitler EP, Giczewska A, Silverstein AP, Al-Khalidi HR, Cha YM, Monahan KH, Bahnson TD, Mark DB, Packer DL, Poole JE, CABANA Investigators Tags: Circulation Source Type: research

Dose Specific Effectiveness and Safety of DOACs in Patients with Non-valvular Atrial Fibrillation: a Canadian Retrospective Cohort Study
Direct oral anticoagulants (DOACs) have been proven to be effective and safe for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). However, suboptimal adherence, variable dosing and use in patient populations that otherwise would have been excluded from clinical trials may impact the efficacy and safety profile of DOACs in a routine care setting. We compared stroke, bleeding, and mortality rates on and off therapy for standard and low-dose DOACs (apixaban, rivaroxaban, dabigatran) versus warfarin in a Canadian cohort.
Source: Thrombosis Research - May 10, 2021 Category: Hematology Authors: Elham Rahme, Richard Godin, Hacene Nedjar, Kaberi Dasgupta, Vicky Tagalakis Source Type: research

Variation in bleeding risk estimates among online calculators: Cross-sectional study of apps used by and for patients with atrial fibrillation
CONCLUSION: Inconsistencies and a lack of precision were observed in annual risk estimates and risk stratification produced by Web and mobile bleeding risk calculators for patients with atrial fibrillation. Clinicians should refer to annual bleeding risks observed in major randomized controlled trials to inform risk estimates communicated to patients.PMID:35418403 | DOI:10.46747/cfp.6804e127
Source: Canadian Family Physician Medecin de Famille Canadien - April 14, 2022 Category: Primary Care Authors: Ryan Pelletier Jeff Nagge John-Michael Gamble Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10